Emavusertib

• CAS: 1801344-14-8
• Catalog Number: ACM1801344148
• Category: Inhibitors
• Molecular Weight: 491.51
• Molecular Formula: C24H25N7O5
• Description: Emavusertib, also known as CA-4948 is a potent IRAK4/FLT3 inhibitor with anti-tumor activity. CA-4948 demonstrated good cellular activity in ABC DLBCL and AML cell lines. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.
• Synonyms: CA-4948; CA 4948; CA4948; Emavusertib
• IUPAC Name: (R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide
• Canonical SMILES: O=C(C1=COC(C2=CC(C)=NC=C2)=N1)NC3=C(N4C[C@H](O)CC4)N=C5C(OC(N6CCOCC6)=N5)=C3
• InChI: InChI=1S/C24H25N7O5/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33)/t16-/m1/s1
• InChI Key: SJHNWSAWWOAWJH-MRXNPFEDSA-N
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Shelf Life: >3 years if stored properly
• Storage: Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
• Alternative CAS: 1801344-14-8; 1801343-74-7 (CA4948-Analog)
• Biological Target: CA-4948 is a potent IRAK4/FLT3 inhibtor.
• Drug Formulation: This drug may be formulated in DMSO
• Elemental Analysis: C, 58.65; H, 5.13; N, 19.95; O, 16.28
• Exact Mass: 491.1917
• HS Tariff Code: 2934.99.9001
• In Vitro Activity: In CA-4948 in vitro experiments, pIRAK1 modulation was observed only at later time points. CA-4948 also exhibited good CYP inhibition profile (IC50 > 50 μM in CYP2C19 and <5% inhibition at 1 μM across CYP3A4, 2D6, 2C9, 2C8, 2B6, and 1A2). CA-4948 was not genotoxic in the in vitro bacterial mutagenesis assay and did not produce any biologically relevant clastogenicity changes in the in vivo micronucleus test in mice.; Reference: ACS Med Chem Lett. 2020 Oct 14;11(12):2374-2381. https://pubmed.ncbi.nlm.nih.gov/33335659/
• In Vivo Activity: In vivo efficacy of CA-4948 was evaluated in an OCI-Ly3 xenograft model through oral route of administration in a once daily dosing regimen. A dose of 200 mg/kg q.d. showed partial tumor regression and a 100 mg/kg q.d. dose showed >90% tumor growth inhibition. The compound was well-tolerated, and there were no overt toxicities at these efficacious doses. Drug concentrations from plasma and tumors were determined at 2 h post final dose administration on day 15. CA-4948 treatment resulted in dose proportional increase in plasma and tumor exposures.; Reference: ACS Med Chem Lett. 2020 Oct 14;11(12):2374-2381. https://pubmed.ncbi.nlm.nih.gov/33335659/
• Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
• Stock Solution Storage: 0-4 °C for short term (days to weeks), or -20 °C for long term (months).